Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Oruka Therapeutics, Inc. (ORKA) had Stock-Based Compensation of $6.97M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-31.82M |
|
-- |
|
-- |
|
$36.43M |
|
$-36.43M |
|
$4.61M |
|
$-31.82M |
|
$-31.82M |
|
$-31.82M |
|
$-31.82M |
|
$-31.82M |
|
$-31.82M |
|
$-36.43M |
|
$-36.84M |
|
55.17M |
|
55.17M |
|
$-0.48 |
|
$-0.48 |
|
| Balance Sheet Financials | |
$395.25M |
|
$0.32M |
|
$109.23M |
|
$504.48M |
|
$16.63M |
|
-- |
|
$1.13M |
|
$17.76M |
|
$483.79M |
|
$486.72M |
|
$486.72M |
|
50.17M |
|
| Cash Flow Statement Financials | |
$-23.58M |
|
$-14.44M |
|
$40.60M |
|
$46.94M |
|
$49.52M |
|
$2.58M |
|
|
Stock-Based Compensation |
$6.97M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
23.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.65M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.58% |
|
-6.54% |
|
-6.31% |
|
-6.54% |
|
$9.70 |
|
$-0.43 |
|
$-0.43 |
|